CalciMedica, Inc. 8-K

What Happened
CalciMedica, Inc. (CALC) announced a securities purchase agreement for a private placement of 18,673,429 units priced at ~$0.8033 each, with expected upfront gross proceeds of approximately $15.0 million (before fees and expenses). The units include common stock or pre‑funded warrants plus rights to receive two types of warrants (Series A and Series B) subject to stockholder approval. The closing is expected on or about June 25, 2026, and Guggenheim Securities is the sole placement agent.

Key Details

• Private placement: 18,673,429 units; Common Stock Unit price $0.8033, Pre‑Funded Warrant Unit price $0.8032.
• Upfront proceeds: ~ $15.0 million; up to an additional ~ $34 million if all Series A and Series B warrants are exercised for cash.
• Insider/affiliate participation: 6,908,996 units purchased by executives, directors and existing large holders (including CEO Rachel Leheny, CBO Eric Roberts, CMO Sudarshan Hebbar, and others).
• Warrants and timing: Pre‑Funded Warrants exercisable at $0.0001 (no expiration); Series A exercise price $0.8033 (expires earlier of 18 months or 30 days after IND clearance for CM5480); Series B exercise price $1.00 (5‑year term). Issuance of Series A/B Warrants and related shares requires stockholder approval.
• Use of proceeds & runway: Company expects net proceeds plus current cash (excluding future warrant exercises) will fund operations into the second half of 2027.
• Clinical program updates: CalciMedica will focus on a pulmonary hypertension strategy — planning a capital‑efficient Phase 1b Auxora (IV CRAC inhibitor) study in PAH with data expected mid‑2027; IND clearance for oral candidate CM5480 anticipated mid‑2027. FDA reviewed a KOURAGE protocol amendment and provided no comments, allowing continued dosing in that study.

Why It Matters
This financing provides near‑term funding to advance CalciMedica’s prioritized pulmonary hypertension program and related IND and early‑stage clinical work, giving the company runway into mid/late‑2027 under its current plan. Insider participation signals support from management and key holders, but issuance of the Series A and B warrants requires stockholder approval and could add dilution only if approved and exercised (up to ~ $34M additional cash if fully exercised). Investors should note the timing and conditional nature of the warrants, the ownership limits tied to warrant exercises (generally a 19.99% cap), and that the company’s stated cash runway excludes any proceeds from future warrant exercises.